Literature DB >> 31567406

Deconstructing Poststroke Delirium in a Prospective Cohort of Patients With Intracerebral Hemorrhage.

Michael E Reznik1,2, Jonathan Drake1, Seth A Margolis1,3, Scott Moody1, Kayleigh Murray1, Samantha Costa1, Ali Mahta1,2, Linda C Wendell1,2,4, Bradford B Thompson1,2, Shyam S Rao1,2, Anna M Barrett5, Olga Boukrina5, Lori A Daiello1, Wael F Asaad2, Karen L Furie1, Richard N Jones1,3.   

Abstract

OBJECTIVES: Poststroke delirium may be underdiagnosed due to the challenges of disentangling delirium symptoms from underlying neurologic deficits. We aimed to determine the prevalence of individual delirium features and the frequency with which they could not be assessed in patients with intracerebral hemorrhage.
DESIGN: Prospective observational cohort study.
SETTING: Neurocritical Care and Stroke Units at a university hospital. PATIENTS: Consecutive patients with intracerebral hemorrhage from February 2018 to May 2018.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: An attending neurointensivist performed 257 total daily assessments for delirium on 60 patients (mean age 68.0 [SD 18.4], 62% male, median intracerebral hemorrhage score 1.5 [interquartile range 1-2], delirium prevalence 57% [n = 34]). Each assessment included the Confusion Assessment Method for the ICU, Intensive Care Delirium Screening Checklist, a focused bedside cognitive examination, chart review, and nurse interview. We characterized individual symptom prevalence and established delirium diagnoses using Diagnostic and Statistical Manual of Mental Disorders, fifth edition criteria, then compared performance of the Confusion Assessment Method for the ICU and Intensive Care Delirium Screening Checklist against reference-standard expert diagnosis. Symptom fluctuation (61% of all assessments), psychomotor changes (46%), sleep-wake disturbances (46%), and impaired arousal (37%) had the highest prevalence and were never rated "unable to assess," while inattention (36%), disorientation (27%), and disorganized thinking (18%) were also common but were often rated 'unable to assess' (32%, 43%, and 44% of assessments, respectively), most frequently due to aphasia (32% of patients). Including nonverbal assessments of attention decreased the frequency of 'unable to assess' ratings to 11%. Since the Intensive Care Delirium Screening Checklist may be positive without the presence of symptoms that require verbal assessment, it was more accurate (sensitivity = 77%, specificity = 97%, area under the receiver operating characteristic curve, 0.87) than the Confusion Assessment Method for the ICU (sensitivity = 41%, specificity = 88%, area under the receiver operating characteristic curve, 0.64).
CONCLUSIONS: Delirium is common after intracerebral hemorrhage, but severe neurologic deficits may confound its assessment and lead to underdiagnosis. The Intensive Care Delirium Screening Checklist's inclusion of nonverbal features may make it more accurate than the Confusion Assessment Method for the ICU in patients with neurologic deficits, but novel tools designed for such patients may be warranted.

Entities:  

Mesh:

Year:  2020        PMID: 31567406     DOI: 10.1097/CCM.0000000000004031

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

Review 1.  Delirium Management in the ICU.

Authors:  Michael E Reznik; Arjen J C Slooter
Journal:  Curr Treat Options Neurol       Date:  2019-11-14       Impact factor: 3.598

2.  Associations Between Stroke Localization and Delirium: A Systematic Review and Meta-Analysis.

Authors:  John Y Rhee; Mia A Colman; Maanasa Mendu; Simran J Shah; Michael D Fox; Natalia S Rost; Eyal Y Kimchi
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-12-23       Impact factor: 2.136

3.  Impact of Delirium on Outcomes After Intracerebral Hemorrhage.

Authors:  Michael E Reznik; Seth A Margolis; Ali Mahta; Linda C Wendell; Bradford B Thompson; Christoph Stretz; James L Rudolph; Olga Boukrina; A M Barrett; Lori A Daiello; Richard N Jones; Karen L Furie
Journal:  Stroke       Date:  2021-10-05       Impact factor: 7.914

4.  Common biomarkers of physiologic stress and associations with delirium in patients with intracerebral hemorrhage.

Authors:  Michael E Reznik; Roshini Kalagara; Scott Moody; Jonathan Drake; Seth A Margolis; Sevdenur Cizginer; Ali Mahta; Shyam S Rao; Christoph Stretz; Linda C Wendell; Bradford B Thompson; Wael F Asaad; Karen L Furie; Richard N Jones; Lori A Daiello
Journal:  J Crit Care       Date:  2021-03-23       Impact factor: 4.298

Review 5.  The Role of Vascular Risk Factors in Post-Stroke Delirium: A Systematic Review and Meta-Analysis.

Authors:  Vasileios Siokas; Robert Fleischmann; Katharina Feil; Ioannis Liampas; Markus C Kowarik; Yang Bai; Maria-Ioanna Stefanou; Sven Poli; Ulf Ziemann; Efthimios Dardiotis; Annerose Mengel
Journal:  J Clin Med       Date:  2022-10-01       Impact factor: 4.964

6.  The impact of delirium on withdrawal of life-sustaining treatment after intracerebral hemorrhage.

Authors:  Michael E Reznik; Scott Moody; Kayleigh Murray; Samantha Costa; Brian Mac Grory; Tracy E Madsen; Ali Mahta; Linda C Wendell; Bradford B Thompson; Shyam S Rao; Christoph Stretz; Kevin N Sheth; David Y Hwang; Darin B Zahuranec; Matthew Schrag; Lori A Daiello; Wael F Asaad; Richard N Jones; Karen L Furie
Journal:  Neurology       Date:  2020-09-10       Impact factor: 9.910

7.  Delirium Screening in Aphasic Patients With the Intensive Care Delirium Screening Checklist (ICDSC): A Prospective Cohort Study.

Authors:  Christian Boßelmann; Jan Zurloh; Maria-Ioanna Stefanou; Vera Stadler; Yvonne Weber; Holger Lerche; Sven Poli; Ulf Ziemann; Annerose Mengel
Journal:  Front Neurol       Date:  2019-11-12       Impact factor: 4.003

8.  Delirium Screening in Neurocritical Care and Stroke Unit Patients: A Pilot Study on the Influence of Neurological Deficits on CAM-ICU and ICDSC Outcome.

Authors:  Judith von Hofen-Hohloch; Carolin Awissus; Marie Michèle Fischer; Dominik Michalski; Jost-Julian Rumpf; Joseph Classen
Journal:  Neurocrit Care       Date:  2020-12       Impact factor: 3.210

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.